z-logo
open-access-imgOpen Access
Bax is involved in the anticancer activity of Velcade in colorectal cancer
Author(s) -
Liya Su,
Qimuge Suyila,
Ling Yang,
Hong Li,
Yaguang Xi,
Xiulan Su
Publication year - 2017
Publication title -
experimental and therapeutic medicine
Language(s) - English
Resource type - Journals
eISSN - 1792-1015
pISSN - 1792-0981
DOI - 10.3892/etm.2017.4857
Subject(s) - apoptosis , cancer research , oncogene , cancer , intrinsic apoptosis , signal transduction , programmed cell death , colorectal cancer , biology , cell cycle , bcl 2 associated x protein , cancer cell , cell , microbiology and biotechnology , caspase , caspase 3 , genetics
Numerous chemotherapeutic agents promote tumor cell death by activating the intrinsic apoptosis signaling pathway. This pathway is regulated by mitochondrial dysfunction, which occurs through an intricate process controlled by complex interactions between B-cell lymphoma 2 (Bcl-2) family members and other cellular proteins. Bcl-2-associated X protein (Bax) is a proapoptotic protein that is an essential component of the intrinsic apoptosis signaling pathway. Patients lacking Bax may be less sensitive to chemotherapy due to an impaired intrinsic apoptosis signaling pathway. The present study demonstrated that Bax expression in colorectal cancer (CRC) tissues was typically increased compared with that in adjacent normal tissues. Furthermore, Bax -/- HCT-116 cells exhibited reduced proliferation and colony formation ability compared with Bax +/+ HCT116 cells, although the rate of apoptosis of these cells remained unchanged. However, Bax -/- HCT116 cells became more resistant to apoptosis when treated with Velcade. The results of the present study provide novel insights into the relevance of Bax expression to the prognosis of CRC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom